Historical Valuation
Cumberland Pharmaceuticals Inc (CPIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 9.91. The fair price of Cumberland Pharmaceuticals Inc (CPIX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.95
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cumberland Pharmaceuticals Inc (CPIX) has a current Price-to-Book (P/B) ratio of 2.28. Compared to its 3-year average P/B ratio of 1.23 , the current P/B ratio is approximately 85.19% higher. Relative to its 5-year average P/B ratio of 1.12, the current P/B ratio is about 103.07% higher. Cumberland Pharmaceuticals Inc (CPIX) has a Forward Free Cash Flow (FCF) yield of approximately 11.31%. Compared to its 3-year average FCF yield of 15.96%, the current FCF yield is approximately -29.11% lower. Relative to its 5-year average FCF yield of 14.91% , the current FCF yield is about -24.14% lower.
P/B
Median3y
1.23
Median5y
1.12
FCF Yield
Median3y
15.96
Median5y
14.91
Competitors Valuation Multiple
AI Analysis for CPIX
The average P/S ratio for CPIX competitors is 44.47, providing a benchmark for relative valuation. Cumberland Pharmaceuticals Inc Corp (CPIX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -8.73%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CPIX
1Y
3Y
5Y
Market capitalization of CPIX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CPIX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CPIX currently overvalued or undervalued?
Cumberland Pharmaceuticals Inc (CPIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 9.91. The fair price of Cumberland Pharmaceuticals Inc (CPIX) is between NaN to NaN according to relative valuation methord.
What is Cumberland Pharmaceuticals Inc (CPIX) fair value?
CPIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cumberland Pharmaceuticals Inc (CPIX) is between NaN to NaN according to relative valuation methord.
How does CPIX's valuation metrics compare to the industry average?
The average P/S ratio for CPIX's competitors is 44.47, providing a benchmark for relative valuation. Cumberland Pharmaceuticals Inc Corp (CPIX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -8.73%, this premium appears unsustainable.
What is the current P/B ratio for Cumberland Pharmaceuticals Inc (CPIX) as of Jan 11 2026?
As of Jan 11 2026, Cumberland Pharmaceuticals Inc (CPIX) has a P/B ratio of 2.28. This indicates that the market values CPIX at 2.28 times its book value.
What is the current FCF Yield for Cumberland Pharmaceuticals Inc (CPIX) as of Jan 11 2026?
As of Jan 11 2026, Cumberland Pharmaceuticals Inc (CPIX) has a FCF Yield of 11.31%. This means that for every dollar of Cumberland Pharmaceuticals Inc’s market capitalization, the company generates 11.31 cents in free cash flow.
What is the current Forward P/E ratio for Cumberland Pharmaceuticals Inc (CPIX) as of Jan 11 2026?
As of Jan 11 2026, Cumberland Pharmaceuticals Inc (CPIX) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Cumberland Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cumberland Pharmaceuticals Inc (CPIX) as of Jan 11 2026?
As of Jan 11 2026, Cumberland Pharmaceuticals Inc (CPIX) has a Forward P/S ratio of 0.00. This means the market is valuing CPIX at $0.00 for every dollar of expected revenue over the next 12 months.